DEF: NeuroPace Sets Annual Meeting for June 5, 2026

NeuroPace, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 5, 2026, to elect directors and ratify the appointment of its independent auditor.

Summary

• NeuroPace, Inc. is holding its Annual Meeting of Stockholders virtually on June 5, 2026, at 10:30 a.m. Pacific time.
• The primary purposes of the meeting are to elect two Class II directors, Lisa Andrade and Scott Huennekens, for terms until the 2029 Annual Meeting, and to ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026.
• Stockholders of record as of April 9, 2026, are entitled to vote.
• The meeting will be conducted via live webcast, with instructions for participation and voting provided in the proxy materials.
• Joseph S. Lacob, a current director, is not seeking reelection.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a standard procedural document for an annual meeting and does not contain new financial performance data or strategic shifts.

Positives

• The company is holding its annual meeting to ensure continued corporate governance and oversight.
• Nominees for director have extensive experience in the medical device and life sciences industries.
• PricewaterhouseCoopers LLP, a reputable accounting firm, has audited the company's financial statements since 1999, indicating a stable auditor relationship.
• The virtual meeting format allows for broader stockholder participation.
• The company has a clear process for stockholder proposals and communication with the Board.

Negatives

• Joseph S. Lacob, a director, is not seeking reelection, which could represent a loss of experience from the board.
• The filing mentions late Section 16(a) filings by Joel Becker and Rebecca Kuhn due to administrative errors, indicating potential minor compliance oversights.

Risks

• The company's business and financial condition could be adversely affected by various risks, as detailed in its Form 10-K (not provided here).
• Potential for broker non-votes on the election of directors, as it is a non-routine matter, which could impact voting outcomes if beneficial owners do not provide voting instructions.
• The FDA's review of the PMA-Supplement for label expansion of the RNS System could impact Dr. Morrell's bonus compensation.

Future Outlook

The filing does not contain specific forward-looking financial guidance. It focuses on the procedural aspects of the upcoming Annual Meeting and the election of directors and ratification of the auditor.

Management Comments

• "You are cordially invited to attend the Annual Meeting online. Whether or not you expect to attend the Annual Meeting, please complete, date, sign and return the proxy mailed to you, or vote over the telephone or the internet as instructed in these materials, as promptly as possible to ensure your representation at the meeting."
• "We believe that independent and effective oversight of our business and affairs is maintained through the composition of our Board of Directors, the leadership of our independent directors and the committees and our governance structures and processes."
• "Our Board of Directors believes that risk management is an important part of establishing, updating and executing on our business strategy."

Industry Context

StockSavvy.ai notes that NeuroPace's proxy statement reflects standard corporate governance practices for a publicly traded company in the medical device sector, focusing on director elections and auditor ratification. The emphasis on virtual meetings aligns with broader trends in corporate communications.

Comparison to Industry Standards

• Director compensation aligns with industry standards, with retainers for board membership and committee chair roles. For example, the $40,000 annual retainer for non-employee board members is comparable to similar-sized medical device companies.
• The equity compensation for directors, including initial and annual option grants, is also in line with common practices to align director interests with shareholders.
• The ratification of PricewaterhouseCoopers LLP as auditor is a common practice, with the firm having a long-standing relationship (since 1999) which is typical for established companies.
• The structure of the board committees (Audit, Compensation, Nominating and Corporate Governance) and their responsibilities are standard for publicly traded companies and align with Nasdaq listing requirements.

Management Changes

Corporate Governance

Related Party Transactions

• On February 13, 2025, NeuroPace repurchased 5,270,845 shares of its common stock from KCK Ltd. for $49.5 million. KCK Ltd. was a holder of more than 10% of the company's outstanding shares at the time.

Stakeholder Impact

• Shareholders: Will vote on director elections and auditor ratification, influencing board composition and oversight.
• Management: Subject to director elections and compensation committee oversight.
• Employees: Benefit from equity compensation plans and standard employee benefits.
• Auditors: PricewaterhouseCoopers LLP's appointment is subject to ratification, impacting their continued role.

Next Steps

• Stockholders to vote on the election of directors and ratification of the independent auditor at the Annual Meeting on June 5, 2026.
• The company will file a Current Report on Form 8-K with preliminary and final voting results after the Annual Meeting.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial performance data, strategic initiatives, or significant risk disclosures that would warrant a change in investment recommendation. The focus is on procedural matters for corporate governance.

Keywords

NeuroPace, Proxy Statement, Annual Meeting, Stockholders, Director Election, Independent Auditor, PricewaterhouseCoopers, Corporate Governance, Virtual Meeting